Top Page
Bristol-Myers Squibb
(NYSE:BMY)
Bristol-Myers Squibb (BMY) vs. SPDR S&P 500 ETF (SPY)
Bristol-Myers Squibb Business Overview & Revenue Model
Bristol-Myers Squibb Key Performance Indicators (KPIs)
Analyzes revenue from different business segments, highlighting which areas drive growth and profitability, and indicating how well the company diversifies its income streams.
Main Street DataBristol-Myers Squibb Earnings Call Summary
Bristol-Myers Squibb Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 48.03B | 48.30B | 45.01B | 46.16B | 46.38B | 42.52B |
| Gross Profit | 31.62B | 27.43B | 25.36B | 26.49B | 26.76B | 21.70B |
| EBITDA | 14.90B | 3.17B | 19.37B | 19.22B | 20.12B | 4.93B |
| Net Income | 6.04B | -8.95B | 8.03B | 6.33B | 6.99B | -8.99B |
Balance Sheet | ||||||
| Total Assets | 96.89B | 92.60B | 95.16B | 96.82B | 109.31B | 118.48B |
| Cash, Cash Equivalents and Short-Term Investments | 16.50B | 10.86B | 12.28B | 9.25B | 17.22B | 16.45B |
| Total Debt | 51.04B | 51.20B | 41.46B | 40.72B | 45.60B | 51.67B |
| Total Liabilities | 78.29B | 76.22B | 65.67B | 65.70B | 73.31B | 80.60B |
| Stockholders Equity | 18.55B | 16.34B | 29.43B | 31.06B | 35.95B | 37.82B |
Cash Flow | ||||||
| Free Cash Flow | 15.30B | 13.94B | 12.65B | 11.95B | 15.23B | 13.30B |
| Operating Cash Flow | 16.62B | 15.19B | 13.86B | 13.07B | 16.21B | 14.05B |
| Investing Cash Flow | -2.87B | -21.35B | -2.29B | -1.06B | -538.00M | -10.86B |
| Financing Cash Flow | -5.96B | 5.13B | -9.42B | -16.96B | -16.22B | -1.15B |
Bristol-Myers Squibb Technical Analysis
Bristol-Myers Squibb Risk Analysis
Bristol-Myers Squibb Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | $230.48B | 12.28 | 39.51% | 3.36% | 1.59% | 58.02% | |
77 Outperform | $155.11B | 19.36 | 40.53% | 2.62% | 2.76% | 6407.19% | |
77 Outperform | $94.26B | 13.27 | 35.62% | 3.54% | 5.97% | 128.66% | |
77 Outperform | $184.00B | 26.42 | 81.71% | 3.15% | 11.03% | 65.22% | |
69 Neutral | $94.97B | 15.75 | 33.84% | 5.30% | 1.26% | ― | |
68 Neutral | $142.48B | 14.61 | 10.59% | 6.76% | 4.44% | 128.96% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Bristol-Myers Squibb Corporate Events
Bristol Myers Squibb Company is a global biopharmaceutical company focused on discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases, primarily in the fields of oncology, immunology, and cardiovascular disease.
On October 30, 2025, Bristol-Myers Squibb announced its financial results for the third quarter of 2025, reporting a 3% increase in total revenues to $12.2 billion, driven by an 18% rise in its Growth Portfolio revenues. The company raised its 2025 revenue guidance to $47.5 billion to $48.0 billion and updated its non-GAAP EPS range to $6.40 to $6.60, reflecting strong business execution and pipeline advancements.
The most recent analyst rating on (BMY) stock is a Buy with a $64.00 price target. To see the full list of analyst forecasts on Bristol-Myers Squibb stock, see the BMY Stock Forecast page.
Study Overview: Bristol-Myers Squibb and BioNTech SE are collaborating on the ROSETTA CRC-203 study, officially titled ‘A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer.’ The study aims to evaluate the safety and efficacy of pumitamig combined with chemotherapy compared to bevacizumab with chemotherapy in patients with advanced colorectal cancer.
Study Overview: The ROSETTA Gastric-204 study, officially titled ‘A Blinded, Randomized, Phase 2/3 Study of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma,’ aims to evaluate the safety and efficacy of Pumitamig combined with chemotherapy compared to Nivolumab with chemotherapy. This study is significant as it explores potential new treatment options for patients with these aggressive cancers.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 clinical study titled A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis. The study aims to assess the effectiveness and safety of BMS-986278, a potential treatment for progressive pulmonary fibrosis, a condition with limited therapeutic options.
Bristol-Myers Squibb Company is conducting a Phase 3 clinical study titled ‘A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy After Autologous Stem Cell Transplantation (ASCT) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) (EXCALIBER-Maintenance)’. The study aims to evaluate the effectiveness of iberdomide maintenance therapy compared to lenalidomide maintenance therapy in patients with newly diagnosed multiple myeloma following an autologous stem cell transplant. This research is significant as it could lead to improved maintenance therapy options for multiple myeloma patients.
Bristol-Myers Squibb Company (BMY) is conducting a Phase 3, open-label extension study titled A Phase 3, Open-label Extension Study to Assess the Long-term Safety of KarXT for the Treatment of Mania or Mania With Mixed Features in Bipolar-I Disorder (BALSAM-3). The study aims to evaluate the long-term safety and tolerability of KarXT in treating mania or mania with mixed features associated with Bipolar-I Disorder (BP-I).
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 clinical trial titled ‘A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Deucravacitinib in Adolescent Participants (12 Years to Less Than 18 Years) With Moderate to Severe Plaque Psoriasis.’ The study aims to assess the effectiveness, safety, and drug levels of Deucravacitinib in adolescents suffering from moderate to severe plaque psoriasis, a condition that significantly impacts quality of life.
Study Overview: Bristol-Myers Squibb Company is conducting a Phase 1 clinical study titled ‘An Open-label, Phase 1, Single Ascending Dose-Finding Study to Characterize the Safety, Tolerability, and Pharmacokinetics of a Long Acting Injectable KarXT Formulation in Participants With Schizophrenia.’ The study aims to assess the safety, tolerability, and drug levels of KarXT, a promising treatment for schizophrenia, highlighting its potential significance in addressing this challenging mental health condition.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 study titled ‘A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer’s Disease (MINDSET 2)’. The study aims to assess the effectiveness and safety of the drug combination KarXT + KarX-EC in treating cognitive impairment associated with mild to moderate Alzheimer’s Disease, a significant concern given the growing prevalence of the condition.
Study Overview: Bristol-Myers Squibb is conducting a study titled A Phase 1/2, Multi-Center, Open-Label, Dose-Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BMS-986458, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed/Refractory Non-Hodgkin Lymphomas (R/R NHL). The study aims to assess the safety and effectiveness of BMS-986458, a new drug targeting B-cell lymphoma 6, in patients with relapsed or refractory non-Hodgkin lymphoma.
Study Overview: Bristol-Myers Squibb is conducting a Phase 1/1b study titled ‘A Phase 1/1b First-in-human Study of BMS-986463 in Advanced Malignant Tumors.’ The study aims to evaluate the safety, tolerability, and efficacy of escalating doses of BMS-986463 in participants with advanced malignant tumors, including High-grade Serous Ovarian Carcinoma, Uterine Serous Carcinoma, and Non-small Cell Lung Cancer. This research is significant as it explores new treatment avenues for these challenging conditions.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 study titled ‘A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated With Mild to Moderate Alzheimer’s Disease (MINDSET 1)’. The study aims to assess the efficacy and safety of the drug combination KarXT + KarX-EC in treating cognitive impairment in Alzheimer’s patients, a significant step in addressing this challenging condition.
Study Overview: Bristol-Myers Squibb is conducting a Phase 1/1b clinical trial titled ‘A Phase 1/1b First-in-human Trial of BMS-986484 as Monotherapy and Combination Therapy in Participants With Advanced Solid Malignancies.’ The study aims to evaluate the safety and tolerability of BMS-986484, both alone and in combination with nivolumab, in patients with advanced solid tumors, including various types of cancer such as non-small cell lung cancer and colorectal carcinoma. This research is significant as it explores new treatment avenues for challenging cancer types.
Study Overview: Bristol-Myers Squibb Company is conducting a Phase 3 trial titled ‘A Randomized, Double Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012+Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide vs Atezolizumab in Combination With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).’ The study aims to compare the efficacy and safety of a new drug combination, BMS-986489, against the existing treatment, Atezolizumab, for patients with extensive-stage small cell lung cancer, a significant area of unmet medical need.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 study titled ‘A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren’s Syndrome (POETYK SjS-1)’. The study aims to assess the safety and efficacy of Deucravacitinib in treating adults with active Sjögren’s Syndrome, a condition characterized by dry mouth and eyes, which can significantly impact quality of life.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 study titled ‘A Phase 3, Randomized, Two-part Study With a 5-week Double-blind Part (Randomized, Parallel-group, Placebo-controlled) Followed by a 52-week Open-label Extension Part to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Patients With Diagnostic and Statistical Manual of Mental Disorders-Fifth Edition (DSM-5) Schizophrenia’. The study aims to assess the efficacy and safety of KarXT in treating acutely psychotic Japanese adults with schizophrenia, a significant mental health condition.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 study titled ‘A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-1)’. The study aims to assess the effectiveness and safety of KarXT in treating manic episodes in individuals with Bipolar-I Disorder, a condition characterized by severe mood swings. This research is significant as it could offer a new treatment option for managing manic symptoms in this population.
Study Overview: Bristol-Myers Squibb is conducting a long-term safety study titled ‘A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants With Moderate-to-Severe Plaque Psoriasis.’ The study aims to evaluate the safety of Deucravacitinib compared to Ustekinumab in treating moderate-to-severe plaque psoriasis, a significant condition affecting many individuals.
Study Overview: Bristol-Myers Squibb is conducting a Phase 2A clinical study titled A Phase 2A, Double-blind, Randomized, Placebo-controlled, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF). The study aims to assess the safety, tolerability, and exposure-response of BMS-986435/MYK-224 in individuals suffering from symptomatic HFpEF, a condition with limited treatment options, highlighting its significance in the medical field.
Study Overview: Bristol-Myers Squibb is conducting a Phase 1 study titled ‘A Phase 1 First-in-human Study of BMS-986500 as Monotherapy in Advanced Solid Tumors and as Combination Therapy in CDK4/6 Inhibitor Pre-treated Advanced Breast Cancer.’ The study aims to evaluate the effectiveness of BMS-986500, both as a standalone treatment and in combination with other drugs, in treating advanced solid tumors and breast cancer. This research is significant as it explores new treatment avenues for patients with limited options.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 study titled A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants With Active Systemic Lupus Erythematosus (SLE) (POETYK SLE-2). The study aims to assess the effectiveness and safety of deucravacitinib compared to a placebo in patients with moderate to severe Systemic Lupus Erythematosus (SLE), a chronic autoimmune disease. This research is significant as it could lead to new treatment options for SLE, potentially improving patient outcomes.
Study Overview: Bristol-Myers Squibb Company is conducting a study titled A Phase 3, Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer’s Disease (ADAGIO-3). The study aims to assess the long-term efficacy and safety of the combined formulation of xanomeline tartrate/trospium chloride in participants with Alzheimer’s Disease-related agitation who have completed previous studies. This research is significant as it addresses a critical need for effective treatments for agitation in Alzheimer’s patients.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 study titled A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2). The study aims to assess the effectiveness of KarXT in treating manic episodes in individuals with Bipolar-I Disorder, focusing on its efficacy compared to a placebo over a three-week inpatient period. This research is significant as it targets a critical aspect of mental health treatment, potentially offering a new therapeutic option for those affected by this condition.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 study titled ‘A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants With Active Systemic Lupus Erythematosus (SLE) (POETYK SLE-1).’ The study aims to assess the effectiveness and safety of deucravacitinib, a promising treatment for individuals with moderate to severe Systemic Lupus Erythematosus (SLE), a chronic autoimmune disease.
In a significant move for cancer treatment, Bristol-Myers Squibb has launched the IZABRIGHT-Lung01 study, officially titled ‘A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Disease Progression on EGFR Tyrosine Kinase Inhibitor Therapy.’ The study aims to evaluate the efficacy of Izalontamab Brengitecan in patients with EGFR-mutated non-small cell lung cancer who have not responded to previous EGFR TKI therapy, potentially offering a new treatment avenue for this challenging condition.
Pfizer and Bristol-Myers Squibb are conducting a Phase 1B study titled ‘A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30).’ The study aims to assess the safety and tolerability of combining elranatamab and iberdomide in treating relapsed or refractory multiple myeloma, a challenging cancer type that affects plasma cells.
In a recent update, Bristol-Myers Squibb Company (BMY) is conducting a Phase 2 study titled A Phase 2, Open-label, Randomized Trial to Evaluate Two Dosing Regimens of Subcutaneous Formulation of Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent NSCLC. The study aims to assess the effectiveness of two dosing regimens of subcutaneous Nivolumab combined with intravenous Ipilimumab and chemotherapy in treating metastatic or recurrent Non-Small Cell Lung Cancer (NSCLC).
Bristol-Myers Squibb Company is conducting a clinical study titled ‘IZABRIGHT-Bladder01: A Randomized, Open-label, Phase 2/3 Trial of Izalontamab Brengitecan Versus Platinum-based Chemotherapy for Metastatic Urothelial Cancer in Participants With Disease Progression on or After an Immunotherapy-based Treatment.’ The study aims to evaluate the efficacy of Izalontamab Brengitecan compared to standard platinum-based chemotherapy in treating metastatic urothelial cancer that has progressed following immunotherapy. This trial is significant as it explores potential advancements in cancer treatment options.
Study Overview: Bristol-Myers Squibb Company is conducting a study titled A Randomized Phase 2/3 Study of BMS-986504 in Combination With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion. The study aims to evaluate the clinical benefit of BMS-986504, a selective MTA-cooperative inhibitor of PRMT5, combined with pembrolizumab and chemotherapy, compared to a placebo combination, for patients with a specific genetic deletion in metastatic non-small cell lung cancer.
Study Overview: Bristol-Myers Squibb Company is conducting a Phase 1/2a study titled ‘A Phase 1/2a, Open-label, Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BMS-986507 (BL-B01D1) Combinations in Adult Participants With Advanced Solid Tumors.’ The study aims to assess the safety, tolerability, drug levels, and initial efficacy of BMS-986507 combinations in adults with advanced solid tumors, including lung and breast cancer.
Bristol-Myers Squibb Company is conducting a Phase 3 clinical study to evaluate the efficacy of a combination of Nivolumab and Relatlimab with chemotherapy against Pembrolizumab with chemotherapy. This study targets patients with stage IV or recurrent non-squamous non-small cell lung cancer, specifically those with PD-L1 expression of 1% or higher. The study aims to determine which treatment regimen offers superior outcomes for this patient group.
Study Overview: Bristol-Myers Squibb is conducting a first-in-human study titled ‘A Phase 1/1b Open-label, Multi-center Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC).’ The study aims to evaluate the safety and tolerability of the drug BMS-986506 when administered alone to participants with advanced ccRCC, a significant step in developing new treatments for this aggressive cancer type.
Study Overview: Bristol-Myers Squibb, in collaboration with Janssen Research & Development, is conducting a Phase 3 study titled A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome. The study aims to demonstrate the efficacy and safety of Milvexian, an oral Factor XIa inhibitor, in reducing major adverse cardiovascular events (MACE) such as cardiovascular death, myocardial infarction, and ischemic stroke, compared to a placebo.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 study titled ‘SUCCESSOR-2’ to evaluate the efficacy of Mezigdomide in combination with Carfilzomib and Dexamethasone (MeziKD) compared to Carfilzomib and Dexamethasone (Kd) alone in patients with relapsed or refractory multiple myeloma. This study aims to determine if the addition of Mezigdomide can improve treatment outcomes for this challenging condition.
Study Overview: Bristol-Myers Squibb is conducting a Phase 2 study titled A Multicenter, Randomized, Open-label, Phase 2 Study Evaluating the Safety and Efficacy of BMS-986504 Monotherapy in Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion After Progression on Prior Therapies. The study aims to assess the safety and efficacy of BMS-986504 in patients with advanced NSCLC who have not responded to previous treatments, highlighting its potential significance in offering new therapeutic options.
Study Overview: Bristol-Myers Squibb is conducting a Phase 2/3 study titled A Phase 2/3, Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Oral Ozanimod (RPC1063) in Pediatric Subjects With Moderately to Severely Active Ulcerative Colitis With an Inadequate Response to Conventional Therapy. The study aims to assess the effectiveness and safety of ozanimod in achieving and maintaining clinical remission in pediatric patients with moderate to severe ulcerative colitis who have not responded well to conventional treatments.
Study Overview: Bristol-Myers Squibb is conducting a study titled ‘A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)’. The study aims to evaluate the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate, compared to standard chemotherapy options in treating specific breast cancer patients who cannot undergo anti-PD(L)1 therapy.
Study Overview: Bristol-Myers Squibb Company is conducting a Phase 3 study titled ‘A Phase 3, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Individuals With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine.’ The study aims to assess the efficacy and safety of KarXT as an additional treatment for mania in patients with Bipolar-I Disorder, highlighting its potential significance in improving mental health outcomes.
Study Overview: Bristol-Myers Squibb is conducting a study titled ‘REal-World Application of Luspatercept in Adults With Transfusion-Dependent Beta-Thalassemia in the Middle East (RELATE).’ The study aims to evaluate the effectiveness of luspatercept in adults suffering from transfusion-dependent beta-thalassemia in the Middle East, providing insights into its real-world application and significance in treating this condition.
Study Overview: Bristol-Myers Squibb is conducting a randomized, Phase 2/3 clinical trial titled A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30). The study aims to evaluate the safety and efficacy of BMS-986504, a selective PRMT5 inhibitor, in combination with standard chemotherapy treatments for patients with a specific genetic deletion in pancreatic cancer. This research is significant as it targets a challenging cancer type with limited treatment options.
Study Overview: Bristol-Myers Squibb is conducting a study titled ‘A Prospective, Open-label, Multicenter, Randomized Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Renal Allograft Recipients Aged 12 to Less Than 18 Years of Age to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications.’ The study aims to assess the benefits and risks associated with switching adolescent kidney transplant recipients to a belatacept-based regimen versus continuing with a calcineurin inhibitor-based regimen, focusing on medication adherence.
Study Overview: Bristol-Myers Squibb Company is conducting a Phase 1/2a, open-label, first-in-human study titled ‘A Phase 1/2a, First-in-human, Open-label Study of BMS-986517 as Monotherapy in Adult Participants With Advanced Solid Tumors.’ The study aims to evaluate the safety and tolerability of BMS-986517 in individuals with advanced solid tumors, marking a significant step in developing new cancer treatments.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 study titled ‘A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer’s Disease.’ The study aims to assess the safety and effectiveness of KarXT + KarX-EC in treating agitation in Alzheimer’s patients, a significant concern due to its impact on patient quality of life and caregiver burden.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 study titled ‘A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer’s Disease.’ The study aims to assess the safety and effectiveness of the drug combination KarXT + KarX-EC in treating agitation in Alzheimer’s patients, a significant concern for both patients and caregivers.
Study Overview: Bristol-Myers Squibb is conducting a Phase 1/2 study titled A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adult Participants With Recurrent or Refractory Classical Hodgkin Lymphoma and Non-Hodgkin Lymphoma. The study aims to evaluate the safety, tolerability, drug levels, and preliminary efficacy of the combination therapy in young patients with these challenging conditions.
Bristol-Myers Squibb is conducting a Phase 1b study titled A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986326 in Adult Participants With Discoid Lupus Erythematosus, Subacute Cutaneous Lupus Erythematosus, or Systemic Lupus Erythematosus. The study aims to assess the safety, tolerability, and effects of the drug BMS-986326 on patients with various forms of lupus, providing crucial insights into its potential therapeutic benefits.
Study Overview: Bristol-Myers Squibb is conducting a clinical study titled ‘A Phase 1/2 Study of BMS-986482 as Monotherapy or Combination Therapy in Participants With Advanced Solid Tumors.’ The study aims to evaluate the safety and efficacy of BMS-986482, both alone and in combination with other drugs, in treating advanced solid tumors. This research is significant as it explores new therapeutic options for a challenging group of cancers.
Study Overview: Bristol-Myers Squibb is conducting a clinical study titled A Phase 1/2a, First-in-human, Randomized, Double-blinded, Placebo-controlled, Dose-finding Study in Healthy Volunteers and Participants With Sickle Cell Disease to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, pH and Food Effect, and Preliminary Efficacy of BMS-986470. The study aims to assess the safety, tolerability, and preliminary efficacy of BMS-986470, a potential treatment for sickle cell disease, marking a significant step in addressing this chronic condition.
Study Overview: Bristol-Myers Squibb is conducting the ELEMENT-MDS trial to evaluate the efficacy and safety of Luspatercept compared to Epoetin Alfa in treating anemia in adults with very low to intermediate-risk Myelodysplastic Syndromes (MDS) who have not previously received erythropoiesis-stimulating agents and are not dependent on blood transfusions. This Phase 3 study aims to provide insights into better treatment options for this patient group.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 study titled ‘A Multicenter, Randomized, Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Pharmacokinetics, Efficacy and Safety of Deucravacitinib (BMS-986165) in Pediatric Subjects With Moderate to Severe Plaque Psoriasis.’ The study aims to assess the drug levels, efficacy, and safety of Deucravacitinib in children aged 4 to under 18 years with moderate to severe plaque psoriasis, highlighting the significance of addressing this condition in a younger population.
Bristol-Myers Squibb Company is currently conducting a clinical study titled ‘A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors.’ The study aims to evaluate the safety, tolerability, and recommended doses of BMS-986340, both alone and in combination with other drugs, for treating various advanced solid tumors. This first-in-human study is significant for its potential to offer new treatment options for hard-to-treat cancers.
Study Overview: Bristol-Myers Squibb is conducting a Phase 4 study titled ‘A Study of Mavacamten in Adults With Obstructive Hypertrophic Cardiomyopathy in India (ROVER)’. The study aims to assess the safety, tolerability, and efficacy of mavacamten in treating adults with symptomatic obstructive hypertrophic cardiomyopathy in India, highlighting its significance in addressing this specific heart condition.
Study Overview: Bristol-Myers Squibb is conducting a Phase 1 study titled ‘A Phase 1, 2-Part, Open-label Study to Evaluate Relative Bioavailability of Alternate Formulations of BMS-986460 in Healthy Adult Male Participants.’ The study aims to assess the safety, tolerability, drug levels, and relative bioavailability of different formulations of the drug BMS-986460 in healthy adult males, highlighting its potential significance in advancing drug formulation research.
Study Overview: Bristol-Myers Squibb is conducting a Phase 1b study titled A 2-Part, Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986454 in Participants With Rheumatoid Arthritis. The study aims to assess the safety, tolerability, and drug levels of BMS-986454, a potential treatment for rheumatoid arthritis, highlighting its significance in addressing this chronic inflammatory disorder.
Study Overview: Bristol-Myers Squibb is conducting a Phase 1 clinical trial titled ‘A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 in Patients With Advanced Solid Tumors With Homozygous MTAP Deletion.’ The study aims to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of MRTX1719 in patients with advanced solid tumors characterized by MTAP gene deletion. This research is significant as it targets a specific genetic alteration, potentially offering new treatment avenues for hard-to-treat cancers.
In a recent update, Bristol-Myers Squibb and ONO Pharmaceutical Co. announced a new clinical study titled ‘A Retrospective Observational Study of Nivolumab in Combination With Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC Patients: Real-World Experience in Taiwan.’ The study aims to evaluate the effectiveness and safety of Nivolumab combined with chemotherapy for patients with non-small cell lung cancer (NSCLC), focusing on pathologic complete response (pCR) and progression-free survival (PFS).
Study Overview: Bristol-Myers Squibb is conducting a prospective, observational study titled Prospective, Observational Study in Participants With Active Systemic Lupus Erythematosus (SLE) (Including Lupus Nephritis) With Inadequate Response to Glucocorticoids and At Least 2 Immunosuppressants. The study aims to assess the efficacy and safety of standard care treatments for patients with active SLE who have not responded adequately to glucocorticoids and multiple immunosuppressants. This research is significant as it seeks to improve treatment strategies for a challenging patient group.
Bristol-Myers Squibb and BioNTech SE have announced a new clinical study titled ‘ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer.’ This Phase III trial aims to evaluate the efficacy and safety of BNT327, known as Pumitamig, in combination with chemotherapy versus a placebo with chemotherapy in patients with inoperable or metastatic triple-negative breast cancer (TNBC) who are ineligible for PD(L)1 therapy due to PD-L1 negative disease. The study is significant as it targets a challenging form of breast cancer with limited treatment options.
Study Overview: Bristol-Myers Squibb is conducting an exploratory Phase 1b/2a study titled ‘An Exploratory Phase 1b/2a Multicenter, Open-Label, Novel-Novel Combination Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of CC-92480 (BMS-986348) in Novel Therapeutic Combinations in Participants With Relapsed or Refractory Multiple Myeloma.’ The study aims to evaluate the safety, drug levels, and effectiveness of CC-92480 in combination with other treatments for patients with relapsed or refractory multiple myeloma, a significant area of unmet medical need.
Study Overview: Bristol-Myers Squibb is conducting a study titled A Continuation Protocol for Deucravacitinib in Patients With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132. The study aims to continue the administration of Deucravacitinib to participants who have completed previous related studies, focusing on the treatment of SLE and DLE/SCLE, which are chronic autoimmune conditions.
Study Overview: Bristol-Myers Squibb Company is conducting a study titled ‘Real-world Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU).’ The study aims to assess treatment satisfaction and preferences among adults with schizophrenia in the U.S. who are prescribed xanomeline and trospium chloride (X/T) therapy. This research is significant as it seeks to enhance understanding of patient experiences with this treatment, potentially informing future therapeutic strategies.
Study Overview: Bristol-Myers Squibb is conducting a Phase 2 clinical study titled A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants and to Evaluate the Safety and Pharmacokinetics in Adolescent Participants With Alpha (α)-Thalassemia. The study aims to assess the efficacy and safety of luspatercept plus best supportive care (BSC) compared to placebo plus BSC in treating anemia in adults with α-thalassemia hemoglobin H (HbH) disease, while also evaluating safety and drug levels in adolescents. This research is significant as it addresses a critical need for effective treatments for α-thalassemia, a condition with limited therapeutic options.
Study Overview: Bristol-Myers Squibb is conducting a retrospective study titled ‘Retrospective Study for Describing Real-World Effectiveness of Nivolumab + Chemotherapy in Neoadjuvant NSCLC in Argentina.’ The study aims to evaluate the real-world effectiveness and safety of using nivolumab combined with chemotherapy in Argentinian patients with resectable non-small cell lung cancer (NSCLC), providing valuable insights into treatment outcomes outside of clinical trial settings.
Study Overview: Bristol-Myers Squibb Company is conducting a Phase 1 study titled ‘A Phase 1 Open-Label, Multi-Center Study to Evaluate Pharmacokinetics, Safety and Tolerability of BMS-986504 in Japanese and Chinese Participants With Advanced Solid Tumors With Homozygous MTAP Deletion.’ The study aims to assess the safety, tolerability, and drug levels of BMS-986504 in participants with advanced solid tumors, marking a significant step in developing targeted cancer therapies.
Study Overview: Bristol-Myers Squibb Company is conducting a Phase IV postmarketing study titled A Phase IV Postmarketing Study Evaluating Ozanimod Concentrations in the Breast Milk of Lactating Women Receiving Ozanimod Therapeutically. The study aims to assess the concentrations of ozanimod and its major metabolites in breast milk and their effects on breastfed infants, which is significant for understanding the safety profile of ozanimod in lactating women.
Study Overview: Bristol-Myers Squibb is conducting a Phase 1 study titled ‘A Phase 1, Double-blind, Placebo-controlled, Randomized Study of the Safety, Tolerability, and Pharmacokinetics of BMS-986419 (Part 1) and a Phase 1 Randomized, Double-blind, Positive-controlled, Placebo-controlled, Parallel, Nested-crossover (Moxifloxacin-placebo) Thorough QT/QTc Study to Evaluate the Effect of Multiple Doses of BMS-986419 on Cardiac Repolarization (Part 2) in Healthy Participants.’ The study aims to assess the safety, tolerability, and pharmacokinetics of BMS-986419, as well as its effects on cardiac repolarization, highlighting its potential significance in cardiac health.
Study Overview: Bristol-Myers Squibb Company is conducting a study titled ‘Real-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab or Nivolumab+Ipilimumab.’ The study aims to evaluate the characteristics, treatment patterns, and outcomes of adults with clinically palpable stage III resectable melanoma using these treatments. This research is significant as it provides insights into real-world applications and effectiveness of these neoadjuvant therapies.
Study Overview: Bristol-Myers Squibb is conducting a Phase 1 study titled ‘A Phase 1, 2-Part, Open-label Study to Evaluate the Pharmacokinetics of Novel KarX (BMS-986519) and KarT (BMS-986520) Prototypes Versus the KarXT (BMS-986510) and KarX-EC (BMS-986519) Reference Following Single Doses, and to Explore the Effect of Food After Multiple Doses of Selected Prototypes in Healthy Adult Participants.’ The study aims to assess the pharmacokinetics of new drug prototypes compared to existing references, with a focus on understanding the impact of food on drug absorption in healthy adults.
Study Overview: Bristol-Myers Squibb, in collaboration with K36 Therapeutics, is conducting a Phase 1 clinical trial titled A Phase 1 Study of KTX-1001, an Oral, First-In-Class, Selective, and Potent MMSET Catalytic Inhibitor That Suppresses H3K36me2 in Patients With Relapsed and Refractory Multiple Myeloma. The study aims to assess the safety of KTX-1001, a novel small molecule inhibitor, in treating relapsed or refractory multiple myeloma (RRMM), a condition with limited treatment options.
Study Overview: Bristol-Myers Squibb is conducting a Phase I study titled ‘Phase I Multicenter, Open-Label, First-in-Human Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double Combination With Azacitidine and in Triple Combination With Azacitidine and Venetoclax in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome.’ The study aims to evaluate the safety, tolerability, and efficacy of BMS-986497, alone and in combination, to determine the recommended dose for treating relapsed or refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
Study Overview: Bristol-Myers Squibb is conducting a study titled ZEPOSIA® (Ozanimod) Ulcerative Colitis Pregnancy Registry: a Prospective, Observational Study on the Safety of Ozanimod Exposure in Pregnant Women With Ulcerative Colitis and Their Offspring. The study aims to assess the safety of ozanimod exposure during pregnancy and its effects on maternal, fetal, and infant outcomes, which is crucial for understanding the implications of this treatment in pregnant women with ulcerative colitis.
Study Overview: Bristol-Myers Squibb is conducting a Phase 1/1b study titled A Phase 1/1b Open-label Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors. The study aims to evaluate the safety, tolerability, and anti-cancer activity of BMS-986488, both alone and in combination with other drugs, in patients with advanced malignant tumors.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 study titled A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Deucravacitinib in Children and Adolescents From 5 to Less Than 18 Years of Age With Active Juvenile Psoriatic Arthritis. The study aims to assess the drug levels, efficacy, and safety of Deucravacitinib in pediatric patients with juvenile psoriatic arthritis, a significant step in addressing this challenging condition.
Study Overview: Bristol-Myers Squibb is conducting a study titled The Deucravacitinib Pregnancy Exposure Study: A Prospective Observational Study of Deucravacitinib Safety in Pregnancy. The study aims to assess the safety of deucravacitinib, a drug used to treat psoriasis, during pregnancy by observing outcomes in pregnant participants exposed to the drug. This research is significant as it seeks to ensure the safety of both mothers and infants when using this treatment.
Study Overview: Bristol-Myers Squibb is conducting a study titled ‘Protocol for Transgene Assay Service’ to evaluate tumor samples for transgene levels in patients who have received their gene-modified cell therapy and developed a second primary malignancy. This study is significant as it aims to enhance the understanding of treatment impacts on conditions like Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Multiple Myeloma.
Study Overview: Bristol-Myers Squibb is conducting a study titled ‘Patient Reported Outcomes and Patient Voice Among Patients Diagnosed With Low Risk Myelodysplastic Syndrome (LR-MDS) or Unexplained Anemia In Japan.’ The study aims to assess the quality of life, experiences, and unmet needs of patients with Low Risk Myelodysplastic Syndrome who are erythropoietin stimulating agent naïve and non-transfusion dependent, as well as those with suspected MDS with unexplained anemia in Japan.
Study Overview: Bristol-Myers Squibb is conducting a study titled A Phase 1/2a, Multicenter, Open-label, First in Human Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors. The study aims to evaluate the safety and efficacy of BMS-986490, alone and in combination with Bevacizumab, for treating advanced solid tumors expressing CEACAM5. This research is significant as it explores new treatment avenues for challenging cancer types.
Study Overview: Bristol-Myers Squibb is conducting a Phase 1/2 study titled ‘A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics, and Efficacy of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3).’ The study aims to evaluate the safety, tolerability, efficacy, and drug levels of Golcadomide in patients with challenging T-cell lymphomas, highlighting its potential significance in advancing cancer treatment options in Japan.
Study Overview: Bristol-Myers Squibb Company is conducting a study titled ‘ZEPOSIA® (Ozanimod) Pregnancy Registry: A Prospective, Observational Study on the Safety of Ozanimod Exposure in Pregnant Women and Their Offspring.’ The study aims to gather data on maternal, fetal, and infant outcomes after exposure to ozanimod during pregnancy, helping participants and physicians make informed treatment decisions regarding multiple sclerosis (MS) during pregnancy.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 clinical study titled ‘A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Psychosis Associated With Alzheimer’s Disease.’ The study aims to assess the safety and effectiveness of the drug combination KarXT + KarX-EC in treating psychosis in Alzheimer’s patients, a significant concern given the increasing prevalence of Alzheimer’s disease.
Study Overview: Bristol-Myers Squibb is conducting a study titled ‘Registry of Psoriasis Health Outcomes: A Longitudinal Real-world Collaboration (RePhlect)’ to evaluate the effectiveness of deucravacitinib in adults with moderate-to-severe plaque psoriasis in France. The study aims to provide real-world data on the treatment’s effectiveness, offering significant insights into its practical application.
Study Overview: Bristol-Myers Squibb is conducting a prospective registry study titled ‘Deliver Insights in Hypertrophic Cardiomyopathy and Observational Outcomes in Real World: United States and European Prospective Registry Study.’ The study aims to assess real-world patient characteristics, treatment patterns, and outcomes in patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) receiving mavacamten or other treatments. This research is significant as it evaluates both the safety and effectiveness of mavacamten in real-world settings across the US and Europe.
Study Overview: Bristol-Myers Squibb is conducting a Phase 1 study titled A Phase 1 Study to Evaluate the Mass Balance, Metabolism, Excretion, and Pharmacokinetics of [14C]-BMS-986504 (MRTX1719) in Patients With Advanced Solid Tumors With Homozygous MTAP Deletion. The study aims to understand how the drug is processed in the body, which is crucial for developing effective treatments for patients with these specific tumor types.
Study Overview: Bristol-Myers Squibb is conducting a prospective observational study titled ‘ADMIRE’ to evaluate the effectiveness of deucravacitinib in treating moderate plaque psoriasis in real-world settings in China. The study aims to gather valuable data on the drug’s performance outside of controlled clinical environments, which is crucial for understanding its practical benefits and potential market impact.
Study Overview: Bristol-Myers Squibb is conducting a study titled ‘Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE).’ The study aims to evaluate the clinical effectiveness of all approved therapies for multiple myeloma in both newly-diagnosed and relapsed/refractory settings. This research is significant as it seeks to provide real-world insights into treatment outcomes, potentially guiding future clinical practices.
The clinical study titled ‘An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors’ aims to evaluate the safety and efficacy of RP1, both as a standalone treatment and in combination with nivolumab, in patients with advanced solid tumors. The study’s primary objectives are to determine the maximum tolerated dose and recommended Phase 2 dose, as well as to assess preliminary efficacy, which holds significant potential for advancing cancer treatment options.
Study Overview: Bristol-Myers Squibb is conducting a Phase 1 study titled A Phase 1 Open-label, 2-Part Crossover Study to Assess the Effect of Acid-reducing Agent Famotidine on the Pharmacokinetics of Afimetoran (BMS-986256) in Healthy Participants. The study aims to determine if famotidine, an acid-reducing agent, affects the drug levels of afimetoran in healthy individuals, which is crucial for understanding potential drug interactions.
Study Overview: Bristol-Myers Squibb, in collaboration with I-Mab Biopharma, is conducting a Phase 1 clinical study titled ‘A Phase 1 Study of TJ033721 in Subjects with Advanced or Metastatic Solid Tumors.’ The study aims to evaluate the safety and tolerability of TJ033721 (givastomig), a novel treatment for advanced or metastatic solid tumors, including gastric and esophageal cancers. This study is significant as it explores a potential new therapeutic option for these challenging conditions.
Study Overview: Bristol-Myers Squibb is conducting a study titled ‘Long-Term Safety Follow-Up Surveillance for Phase 3 Trial (KarMMA-9/CA089-1043)’ to evaluate the long-term safety of idecabtagene vicleucel in adults with newly diagnosed multiple myeloma in Korea. The study aims to compare the efficacy and safety of idecabtagene vicleucel with lenalidomide maintenance therapy versus lenalidomide maintenance therapy alone in patients who have a suboptimal response after autologous stem cell transplantation.
Study Overview: Bristol-Myers Squibb is conducting a French, prospective, observational study titled ‘A French, Prospective, Observational, Multicenter Study of Patients Treated With Nivolumab Plus Chemotherapy as First Line Treatment in Advanced or Metastatic Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma or Gastric Adenocarcinoma [METAGIO]’. The study aims to estimate overall survival in real-life conditions for patients in France with advanced or metastatic esophageal, gastroesophageal, or gastric cancers treated with nivolumab and chemotherapy.
Study Overview: Bristol-Myers Squibb Company is conducting a study titled ‘Real-World Camzyos Patient Reported OutcoMes Through PAtient SurveyS in Hypertrophic CardioMyopathy (COMPASS-HCM): A Prospective Longitudinal Study’. The study aims to assess changes in health status among patients with symptomatic obstructive hypertrophic cardiomyopathy treated with mavacamten. This research is significant as it provides real-world insights into patient outcomes, potentially influencing treatment approaches.
Study Overview: Bristol-Myers Squibb Company is conducting a study titled ‘CAMZYOS® (Mavacamten) Post-Marketing Surveillance in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).’ The study aims to evaluate the real-world safety of mavacamten, a treatment for oHCM in adult patients in Korea. This observational study is significant as it provides insights into the drug’s safety profile post-marketing.
Study Overview: Bristol-Myers Squibb is conducting a post-marketing surveillance study titled ‘Onureg® (Oral Azacitidine) Post-Marketing Surveillance in Korean Patients With Acute Myeloid Leukemia.’ The study aims to evaluate the real-world safety of oral azacitidine as a maintenance therapy for Korean patients with acute myeloid leukemia (AML) who have achieved complete remission but are not eligible for stem cell transplantation. This research is significant as it provides insights into the drug’s safety profile in a real-world setting.
Study Overview: Bristol-Myers Squibb is conducting a post-marketing surveillance study titled ‘Reblozyl® (Luspatercept) Post-Marketing Surveillance in Korean Patients With Myelodysplastic Syndrome or Beta Thalassemia.’ The study aims to assess the real-world safety of luspatercept in Korean patients with these conditions, providing valuable insights into its safety profile in a real-world setting.
Study Overview: Bristol-Myers Squibb Company is conducting a post-marketing surveillance study titled Inrebic® (Fedratinib) Post-Marketing Surveillance in Korean Patients With Myelofibrosis. The study aims to assess the real-world safety of fedratinib in adult patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis who have previously been treated with ruxolitinib. This research is significant as it evaluates the treatment’s safety in a real-world setting, particularly for patients who have not responded adequately to or are intolerant of ruxolitinib.
Study Overview: Bristol-Myers Squibb is conducting a study titled Sotyktu (Deucravacitinib) Post-Marketing Surveillance in Korean Patients With Moderate-to-Severe Plaque Psoriasis. The study aims to evaluate the real-world safety and effectiveness of deucravacitinib in patients with moderate-to-severe plaque psoriasis in Korea, highlighting its significance in offering insights into the drug’s performance outside of controlled clinical settings.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 study titled ‘A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-1)’. The study aims to assess the efficacy and safety of KarXT in treating manic episodes in individuals with Bipolar-I Disorder, a significant step in addressing mental health challenges.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 study titled A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy as First-line Treatment for Participants With Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and With Tumor Cell PD-L1 Expression ≥ 1%. The study aims to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with chemotherapy in treating advanced non-squamous non-small cell lung cancer with PD-L1 expression ≥ 1%.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 study titled A Phase 3, Randomized, Two-part Study With a 5-week Double-blind Part (Randomized, Parallel-group, Placebo-controlled) Followed by a 52-week Open-label Extension Part to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Patients With Diagnostic and Statistical Manual of Mental Disorders-Fifth Edition (DSM-5) Schizophrenia. The study aims to assess the efficacy and safety of KarXT in Japanese adults with acute psychosis due to schizophrenia, highlighting its potential significance in addressing mental health challenges.
Study Overview: Bristol-Myers Squibb is conducting a Phase 2 study titled A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants and to Evaluate the Safety and Pharmacokinetics in Adolescent Participants With Alpha (α)-Thalassemia. The study aims to assess the efficacy and safety of luspatercept in treating anemia in adults with α-thalassemia hemoglobin H disease and to evaluate safety and drug levels in adolescents. This study is significant as it could offer new treatment options for this genetic blood disorder.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 open-label extension study titled ‘A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer’s Disease (ADAGIO-3)’. The study aims to assess the long-term safety and effectiveness of the drug combination KarXT and KarX-EC in treating agitation in Alzheimer’s patients who have completed previous related studies. This research is significant as it addresses a critical need for effective treatments for agitation in Alzheimer’s disease.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 study titled ‘A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated With Mild to Moderate Alzheimer’s Disease (MINDSET 1).’ The study aims to assess the efficacy and safety of the drug combination KarXT + KarX-EC in treating cognitive impairment in Alzheimer’s patients, a significant area of unmet medical need.
Study Overview: Bristol-Myers Squibb Company is initiating a study titled ‘Real-world Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU).’ The study aims to assess treatment satisfaction and preferences among adults with schizophrenia in the United States who are prescribed xanomeline and trospium chloride (X/T) therapy. This research is significant as it seeks to provide insights into patient satisfaction with this treatment, potentially influencing prescribing practices and patient outcomes.
Study Overview: Bristol-Myers Squibb is conducting a Phase 1 clinical study titled A Phase 1 First-in-human Study of BMS-986500 as Monotherapy in Advanced Solid Tumors and as Combination Therapy in CDK4/6 Inhibitor Pre-treated Advanced Breast Cancer. The study aims to evaluate the efficacy of BMS-986500 both as a standalone treatment and in combination with other drugs for patients with advanced solid tumors and breast cancer. This research is significant as it explores new therapeutic options for challenging cancer types.
In a significant development, Bristol-Myers Squibb Company is conducting a Phase 3 study titled A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer’s Disease. The study aims to assess the safety and efficacy of the drug combination KarXT + KarX-EC in treating agitation in Alzheimer’s patients, a condition that significantly impacts patient quality of life and caregiver burden.
Study Overview: Bristol-Myers Squibb Company has completed a study titled Real-world Utilization Patterns, Clinical Outcomes, and HCRU in Lower-risk MDS Patients Treated With Luspatercept: A Multinational Medical Record Review Study. The study aimed to understand the treatment use of luspatercept in adults diagnosed with lower-risk myelodysplastic syndromes (MDS), providing insights into treatment patterns and healthcare resource utilization.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 trial titled A Randomized, Double Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012+Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide vs Atezolizumab in Combination With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS). The study aims to compare the efficacy and safety of a new drug combination, BMS-986489, against an existing treatment, Atezolizumab, for patients with extensive-stage small cell lung cancer.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 clinical trial titled ‘A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis.’ The study aims to assess the effectiveness, safety, and tolerability of the drug BMS-986278 in treating progressive pulmonary fibrosis, a condition that leads to scarring of the lungs and affects breathing.
Bristol-Myers Squibb Company is conducting a Phase 3 study titled ‘EXCALIBER-Maintenance’ to evaluate the effectiveness of iberdomide maintenance therapy compared to lenalidomide maintenance therapy in patients with newly diagnosed multiple myeloma following autologous stem cell transplantation. The study aims to determine which treatment offers better outcomes for patients, potentially setting a new standard in maintenance therapy for this condition.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 clinical trial titled ‘A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer’s Disease (ADAGIO-2).’ The study aims to assess the safety and effectiveness of the drug combination KarXT + KarX-EC in treating agitation in Alzheimer’s patients, a significant concern due to its impact on patient quality of life and caregiver burden.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 study titled ‘A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants With Active Systemic Lupus Erythematosus (SLE) (POETYK SLE-2)’. The study aims to assess the effectiveness and safety of deucravacitinib compared to a placebo in individuals with moderate to severe SLE, a chronic autoimmune disease.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 trial titled Randomized, Open-label, Multicenter, Phase 3 Trial of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3). The study aims to evaluate the efficacy and safety of repotrectinib compared to crizotinib in treating this specific type of lung cancer, which is significant for advancing treatment options for patients who have not previously received TKI therapy.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 clinical trial, titled ‘ELEMENT-MDS,’ to evaluate the efficacy and safety of Luspatercept compared to Epoetin Alfa in treating anemia in patients with very low, low, or intermediate-risk Myelodysplastic Syndrome (MDS) who have not previously received erythropoiesis-stimulating agents and are not dependent on blood transfusions. This study aims to provide insights into alternative treatments for MDS-related anemia, potentially improving patient outcomes.
Study Overview: Bristol-Myers Squibb is conducting a study titled ‘A Randomized, Phase 2/3 Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma Harboring Homozygous MTAP Deletion.’ The study aims to assess the safety and effectiveness of BMS-986504, a selective PRMT5 inhibitor, in treating pancreatic cancer patients with a specific genetic deletion.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 study titled ‘A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-1).’ The study aims to assess the effectiveness and safety of KarXT in treating manic episodes in patients with Bipolar-I Disorder, a significant area of unmet medical need.
Study Overview: Bristol-Myers Squibb is conducting a Phase 2 clinical study titled A Phase 2, Study for the Treatment of Anemia With Alpha (α)-Thalassemia to Determine the Efficacy and Safety of Luspatercept (BMS-986346/ACE-536) in Adults and Evaluate the Safety and Pharmacokinetics in Adolescents. The study aims to assess the efficacy and safety of luspatercept in treating anemia in adult patients with α-thalassemia hemoglobin H disease and to evaluate its safety and pharmacokinetics in adolescents. This research is significant as it addresses a critical need for effective treatments in this patient population.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 study titled A Phase 3, Randomized, Two-part Study With a 5-week Double-blind Part (Randomized, Parallel-group, Placebo-controlled) Followed by a 52-week Open-label Extension Part to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Patients With Diagnostic and Statistical Manual of Mental Disorders-Fifth Edition (DSM-5) Schizophrenia. The study aims to assess the efficacy and safety of KarXT in treating acutely psychotic Japanese adults with schizophrenia, a condition with significant impact on mental health.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 clinical trial titled ‘A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated With Mild to Moderate Alzheimer’s Disease (MINDSET 1)’. The study aims to assess the efficacy and safety of the drug combination KarXT + KarX-EC in treating cognitive impairment in patients with mild to moderate Alzheimer’s Disease, a significant area of unmet medical need.
Study Overview: Bristol-Myers Squibb is conducting a study titled ‘Real-world Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)’ to assess treatment satisfaction among adults with schizophrenia in the U.S. prescribed xanomeline and trospium chloride (X/T) therapy. This study aims to provide insights into patient preferences and satisfaction, which are crucial for improving treatment strategies.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 study titled ‘A Phase 3, Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer’s Disease (ADAGIO-3)’. The study aims to assess the long-term efficacy and safety of the drug combination KarXT and KarX-EC in patients with Alzheimer’s-related agitation who have completed prior studies. This research is significant as it addresses a critical need for effective treatments for agitation in Alzheimer’s patients.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 clinical study to evaluate the efficacy of a combination treatment of Nivolumab and Relatlimab with chemotherapy compared to Pembrolizumab with chemotherapy. This study targets patients with stage IV or recurrent non-squamous non-small cell lung cancer exhibiting PD-L1 expression of 1% or higher. The study aims to establish a more effective first-line treatment option, which could significantly impact patient outcomes and treatment standards.
Study Overview: Bristol-Myers Squibb is conducting a Phase 1 clinical study titled ‘A Phase 1 First-in-human Study of BMS-986500 as Monotherapy in Advanced Solid Tumors and as Combination Therapy in CDK4/6 Inhibitor Pre-treated Advanced Breast Cancer.’ The study aims to evaluate the safety and efficacy of BMS-986500, both as a standalone treatment and in combination with other drugs, in patients with advanced solid tumors and breast cancer. This research is significant as it explores new treatment avenues for challenging cancer cases.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 clinical study titled A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants With Active Systemic Lupus Erythematosus (SLE) (POETYK SLE-2). The study aims to assess the effectiveness and safety of deucravacitinib compared to a placebo in patients with moderate to severe SLE, a chronic autoimmune disease. This research is significant as it could lead to a new treatment option for SLE patients.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 clinical study titled A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer’s Disease. The study aims to assess the safety and effectiveness of KarXT + KarX-EC in treating agitation in adults with Alzheimer’s Disease, a significant concern for patients and caregivers.
Study Overview: Bristol-Myers Squibb is conducting the ELEMENT-MDS trial, a Phase 3 study aimed at comparing the efficacy and safety of Luspatercept versus Epoetin Alfa in treating anemia in adults with very low, low, or intermediate-risk Myelodysplastic Syndrome (MDS) who are not receiving blood transfusions. This study is significant as it targets ESA-naïve participants, potentially offering a new therapeutic option for this patient group.
Study Overview: Bristol-Myers Squibb Company is conducting a study titled A Randomized, Phase 2/3 Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma Harboring Homozygous MTAP Deletion. The study aims to evaluate the safety and efficacy of BMS-986504, a selective PRMT5 inhibitor, in combination with standard chemotherapy drugs in patients with a specific genetic deletion, potentially offering a new treatment avenue for this aggressive cancer.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 clinical trial titled ‘Randomized, Open-label, Multicenter, Phase 3 Trial of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)’. The study aims to assess the efficacy and safety of two drugs, repotrectinib and crizotinib, in treating patients with a specific type of lung cancer. This research is significant as it could lead to improved treatment options for NSCLC patients.
Study Overview: Bristol-Myers Squibb is conducting a Phase 1/2 study titled A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors. The study aims to evaluate the safety, tolerability, and recommended doses of BMS-986340, alone and in combination with other drugs, for treating advanced solid tumors. This first-in-human study is significant as it explores new treatment avenues for challenging cancer types.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 study titled ‘A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer’s Disease (ADAGIO-2)’. The study aims to assess the safety and effectiveness of the drug combination KarXT + KarX-EC in treating agitation in Alzheimer’s patients, a significant concern due to its impact on patient quality of life and caregiver burden.
Bristol-Myers Squibb Company (BMY) has announced a new clinical study aimed at evaluating the efficacy of BMS-986504 in combination with pembrolizumab and chemotherapy for first-line treatment of metastatic non-small cell lung cancer (NSCLC) in patients with homozygous MTAP deletion. This study, titled ‘A Randomized Phase 2/3 Study of BMS-986504 in Combination With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion,’ seeks to determine the clinical benefits of this novel combination therapy.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 study titled ‘A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer’s Disease (ADAGIO-1).’ The study aims to assess the safety and efficacy of the drug combination KarXT + KarX-EC in treating agitation in Alzheimer’s patients, a significant concern as it affects patient quality of life and caregiver burden.
The Pan-Tumor Rollover Study, officially titled ‘Pan-Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS Sponsored Trials Investigating Nivolumab and Other Cancer Therapies,’ aims to evaluate the long-term safety of nivolumab monotherapy and its combinations with other cancer therapies across various tumor types. This study is significant as it explores sustained treatment options for patients who have previously participated in Bristol-Myers Squibb (BMS) trials.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 clinical study titled A Multicenter, Randomized, Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Pharmacokinetics, Efficacy and Safety of Deucravacitinib (BMS-986165) in Pediatric Subjects With Moderate to Severe Plaque Psoriasis. The study aims to assess the drug levels, efficacy, and safety of Deucravacitinib in children aged 4 to under 18 years with moderate to severe plaque psoriasis, highlighting its potential impact on pediatric dermatological treatments.
Study Overview: Bristol-Myers Squibb is conducting a Phase 2A study titled A Phase 2A, Double-blind, Randomized, Placebo-controlled, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF). The study aims to assess the safety and effectiveness of the drug BMS-986435/MYK-224 in treating patients with HFpEF, a condition with limited treatment options, highlighting its potential significance in cardiovascular therapy.
Study Overview: Bristol-Myers Squibb is conducting a Phase 1/2a clinical study titled A Phase 1/2a, First-in-human, Randomized, Double-blinded, Placebo-controlled, Dose-finding Study in Healthy Volunteers and Participants With Sickle Cell Disease to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, pH and Food Effect, and Preliminary Efficacy of BMS-986470. The study aims to assess the safety, tolerability, and preliminary efficacy of BMS-986470, a potential treatment for sickle cell disease, highlighting its significance in addressing this chronic condition.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 clinical trial titled ‘Randomized, Open-label, Multicenter, Phase 3 Trial of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)’. The study aims to evaluate the efficacy and safety of two drugs, repotrectinib and crizotinib, in treating patients with this specific type of lung cancer. This research is significant as it explores potential advancements in targeted cancer therapies.
Study Overview: Bristol-Myers Squibb is conducting a Phase 2/3 clinical study titled A Phase 2/3, Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Oral Ozanimod (RPC1063) in Pediatric Subjects With Moderately to Severely Active Ulcerative Colitis With an Inadequate Response to Conventional Therapy. The study aims to assess the effectiveness and safety of ozanimod in achieving and maintaining clinical remission in pediatric patients with moderate to severe ulcerative colitis who have not responded adequately to conventional treatments.
Study Overview: Bristol-Myers Squibb, in collaboration with Janssen Research & Development, is conducting a Phase 3 clinical trial titled A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation. The study aims to evaluate the efficacy and safety of milvexian, an oral Factor XIa inhibitor, compared to apixaban in reducing the risk of stroke and non-CNS systemic embolism in patients with atrial fibrillation. This study is significant as it explores a potentially new treatment option for a common heart condition.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3, open-label extension study titled ‘A Phase 3, Open-label Extension Study to Assess the Long-term Safety of KarXT for the Treatment of Mania or Mania With Mixed Features in Bipolar-I Disorder (BALSAM-3)’. The study aims to evaluate the long-term safety and tolerability of KarXT in treating manic episodes associated with Bipolar-I disorder, which is crucial for understanding the drug’s sustained impact on patients.
Study Overview: Bristol-Myers Squibb Company, in collaboration with Janssen Research & Development, LLC, is conducting a Phase 3 study titled A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome. The study aims to evaluate the efficacy and safety of Milvexian, an oral Factor XIa inhibitor, in reducing the risk of major adverse cardiovascular events (MACE) such as cardiovascular death, myocardial infarction, and ischemic stroke, compared to a placebo.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 study titled ‘A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren’s Syndrome (POETYK SjS-1)’. The study aims to assess the safety and effectiveness of Deucravacitinib, a promising treatment for Sjögren’s Syndrome, a chronic autoimmune disease. This research is significant as it could lead to a new therapeutic option for patients with limited treatment choices.
Bristol-Myers Squibb Company is currently conducting a Phase 3 clinical study titled ‘A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)’. The study aims to assess the effectiveness of KarXT in treating manic episodes in individuals with Bipolar-I Disorder, a significant mental health condition.
Study Overview: Bristol-Myers Squibb Company initiated a study titled A Phase 2a, Open-label, Pilot Study to Evaluate Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of MYK-224 in Participants With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction (MERCUTIO). The study aimed to assess the safety and effectiveness of MYK-224 in treating obstructive Hypertrophic Cardiomyopathy, a condition characterized by thickened heart muscles that can obstruct blood flow.
The recent clinical study update from Bristol-Myers Squibb Company and Incyte Corporation, titled A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204), aims to evaluate the safety, tolerability, and efficacy of combining Epacadostat with Nivolumab in treating various advanced cancers. This study is significant as it explores potential new treatment combinations for challenging cancer types.
Pfizer and Bristol-Myers Squibb are conducting a study titled A Phase 1B, Open-Label Study of Elranatamab in Combination with Iberdomide in Participants with Relapsed Refractory Multiple Myeloma. The study aims to evaluate the safety and tolerability of combining elranatamab and iberdomide for treating relapsed or refractory multiple myeloma, a challenging form of cancer that resists treatment or returns after improvement.
Study Overview: Bristol-Myers Squibb is conducting a Phase 1 study titled ‘A Phase 1, Randomized, Open-label, Parallel, Single-dose Study to Assess the Pharmacokinetics, Tolerability, and Absolute Bioavailability of Subcutaneous Administration of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Healthy Participants.’ The study aims to evaluate the drug levels, tolerability, and biological availability of a single subcutaneous dose of BMS-986446 in healthy individuals, which could provide insights into its potential therapeutic applications.
Study Overview: Bristol-Myers Squibb Company is conducting a study titled ‘A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants With Moderate-to-Severe Plaque Psoriasis.’ The study aims to evaluate the long-term safety of the drug Deucravacitinib compared to Ustekinumab in individuals with psoriasis, a significant step in understanding treatment options for this condition.
Study Overview: Bristol-Myers Squibb is conducting a Phase 1/2 study titled A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors. The study aims to evaluate the safety, tolerability, and recommended doses of BMS-986340, both alone and in combination with other drugs, for patients with advanced solid tumors. This first-in-human study is significant as it explores new treatment avenues for these challenging conditions.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 clinical study titled A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2). The study aims to assess the efficacy of KarXT in treating manic episodes in individuals with Bipolar-I Disorder, highlighting its potential significance in improving mental health treatments.
In a recent clinical study update, Bristol-Myers Squibb Company (BMY) is evaluating the efficacy and safety of Deucravacitinib in adults with active Sjögren’s Syndrome. Officially titled ‘A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren’s Syndrome (POETYK SjS-1)’, the study aims to assess the therapeutic potential of Deucravacitinib, a promising drug candidate, in treating this chronic autoimmune condition.
Study Overview: Bristol-Myers Squibb recently updated its clinical study titled A Phase 2a, Open-label, Pilot Study to Evaluate Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of MYK-224 in Participants With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction (MERCUTIO). The study aimed to assess the safety, efficacy, and tolerability of MYK-224 in patients with obstructive Hypertrophic Cardiomyopathy (oHCM), a condition that causes thickening of the heart muscle, leading to obstruction of blood flow.
Bristol-Myers Squibb Company has announced a new clinical study, titled ‘IZABRIGHT-Bladder01: A Randomized, Open-label, Phase 2/3 Trial of Izalontamab Brengitecan Versus Platinum-based Chemotherapy for Metastatic Urothelial Cancer in Participants With Disease Progression on or After an Immunotherapy-based Treatment.’ The study aims to evaluate the efficacy of Izalontamab Brengitecan compared to traditional platinum-based chemotherapy in patients whose cancer has progressed following immunotherapy. This research is significant as it explores new treatment avenues for metastatic urothelial cancer, potentially improving patient outcomes.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 study titled ‘A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants With Active Systemic Lupus Erythematosus (SLE) (POETYK SLE-1)’. The study aims to assess the effectiveness and safety of deucravacitinib compared to a placebo in individuals with moderate to severe SLE, a significant autoimmune disease affecting multiple organs.
Study Overview: Bristol-Myers Squibb Company is conducting a Phase IV postmarketing study titled ‘A Lactation Study in Women Receiving Treatment With Ozanimod.’ The study aims to evaluate the concentrations of ozanimod and its major metabolites in the breast milk of lactating women and assess the effects on breastfed infants. This research is significant as it provides insights into the safety and implications of ozanimod use during lactation.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 study titled ‘A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis.’ The study aims to assess the effectiveness, safety, and tolerability of the drug BMS-986278 in treating idiopathic pulmonary fibrosis, a chronic lung disease with limited treatment options.
Study Overview: Bristol-Myers Squibb is conducting a Phase 2/3 trial titled ‘IZABRIGHT-Bladder01,’ which aims to compare the effectiveness of Izalontamab Brengitecan against platinum-based chemotherapy for patients with metastatic urothelial cancer who have experienced disease progression following immunotherapy. This study is significant as it explores new treatment avenues for a challenging cancer type.
Study Overview: Bristol-Myers Squibb Company is conducting a study titled ‘Real-world Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU).’ The study aims to assess treatment satisfaction among adults with schizophrenia in the United States who are prescribed xanomeline and trospium chloride (XT) therapy. This research is significant as it seeks to provide insights into patient preferences and satisfaction with this specific treatment regimen.
In a recent clinical study update, Bristol-Myers Squibb Company (BMY) is conducting a Phase 3 trial titled ‘A Randomized, Double Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012+Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide vs Atezolizumab in Combination With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).’ The study aims to compare the efficacy and safety of the BMS-986489 combination therapy against Atezolizumab, both paired with Carboplatin and Etoposide, in treating extensive-stage small cell lung cancer.
Bristol-Myers Squibb’s recent earnings call painted a picture of both optimism and caution. The company showcased strong performance in its growth portfolio, which led to an increase in revenue guidance, reflecting confidence in its strategic direction. However, challenges such as unmet expectations in certain Phase III trials and the decline of its legacy portfolio were also acknowledged.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 study titled A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-1). The study aims to assess the effectiveness and safety of KarXT in treating manic episodes in individuals with Bipolar-I Disorder, highlighting its potential significance in improving mental health treatments.
Study Overview: Bristol-Myers Squibb is initiating a Phase 3 clinical study titled A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Deucravacitinib in Adolescent Participants (12 Years to Less Than 18 Years) With Moderate to Severe Plaque Psoriasis. The study aims to assess the effectiveness, safety, and drug levels of Deucravacitinib, a promising treatment for adolescents suffering from moderate to severe plaque psoriasis.
Bristol-Myers Squibb Company (BMY) is conducting a Phase 1/2a study titled ‘A Phase 1/2a, Open-label, Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BMS-986507 (BL-B01D1) Combinations in Adult Participants With Advanced Solid Tumors.’ The study aims to assess the safety, tolerability, drug levels, and preliminary efficacy of BMS-986507 combinations in adults with advanced solid tumors, marking a significant step in cancer treatment research.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 study titled ‘A Phase 3, Randomized, Two-part Study With a 5-week Double-blind Part (Randomized, Parallel-group, Placebo-controlled) Followed by a 52-week Open-label Extension Part to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Patients With DSM-5 Schizophrenia.’ The study aims to assess the efficacy and safety of KarXT in treating acutely psychotic Japanese adults with schizophrenia, a significant step in addressing mental health challenges.
Bristol-Myers Squibb Company (BMY) is currently conducting a Phase 1b clinical study titled A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986326 in Adult Participants With Discoid Lupus Erythematosus, Subacute Cutaneous Lupus Erythematosus, or Systemic Lupus Erythematosus. The study aims to assess the safety, tolerability, and drug effects of BMS-986326 in adults with various forms of lupus, which is significant for advancing treatment options for this challenging condition.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 study titled A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy as First-line Treatment for Participants With Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and With Tumor Cell PD-L1 Expression ≥ 1%. The study aims to compare the efficacy of Nivolumab and Relatlimab combined with chemotherapy against Pembrolizumab with chemotherapy in treating advanced non-squamous non-small cell lung cancer with PD-L1 expression ≥ 1%.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 study titled ‘SUCCESSOR-2’ to evaluate the efficacy of Mezigdomide in combination with Carfilzomib and Dexamethasone (MeziKD) versus Carfilzomib and Dexamethasone (Kd) in patients with relapsed or refractory multiple myeloma (RRMM). The study aims to determine if the addition of Mezigdomide improves treatment outcomes, which could signify a significant advancement in RRMM therapy.
Study Overview: Bristol-Myers Squibb is conducting a study titled ‘A Randomized, Phase 2/3 Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma Harboring Homozygous MTAP Deletion.’ The study aims to evaluate the safety and effectiveness of BMS-986504, a selective inhibitor, in treating pancreatic cancer patients with a specific genetic deletion.
The Pan-Tumor Rollover Study, officially titled ‘Pan-Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS Sponsored Trials Investigating Nivolumab and Other Cancer Therapies,’ aims to assess the long-term safety of nivolumab monotherapy and its combinations with other cancer therapies across various tumor types. This study is significant as it explores the extended use of these treatments, potentially offering new insights into cancer management.
Bristol-Myers Squibb Company is a global biopharmaceutical company focused on discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases, primarily in the sectors of oncology, immunology, and cardiovascular diseases.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 study titled ‘A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis.’ The study aims to assess the effectiveness and safety of BMS-986278, a potential treatment for progressive pulmonary fibrosis, a condition characterized by scarring of lung tissue that leads to severe breathing difficulties.
Pfizer Inc. and Bristol-Myers Squibb Company are conducting a Phase 1B study titled ‘A PHASE 1B, OPEN-LABEL STUDY OF ELRANATAMAB IN COMBINATION WITH IBERDOMIDE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA.’ The study aims to evaluate the safety and tolerability of combining elranatamab with iberdomide in patients with relapsed or refractory multiple myeloma, a cancer affecting plasma cells.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 study titled A Phase 3, Open-label Extension Study to Assess the Long-term Safety of KarXT for the Treatment of Mania or Mania With Mixed Features in Bipolar-I Disorder (BALSAM-3). The primary goal is to evaluate the long-term safety and tolerability of KarXT in treating manic episodes in Bipolar-I Disorder, a significant step in addressing mental health treatment needs.
Study Overview: Bristol-Myers Squibb is conducting a clinical study titled A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors. The study aims to evaluate the safety, tolerability, and optimal dosing of BMS-986340, both alone and combined with other drugs, in patients with advanced solid tumors. This first-in-human study is significant as it explores new treatment avenues for challenging cancer cases.
Study Overview: Bristol-Myers Squibb is conducting a Phase 1/1b clinical trial titled A Phase 1/1b First-in-human Study of BMS-986463 in Advanced Malignant Tumors. The study aims to assess the safety, tolerability, and efficacy of escalating doses of BMS-986463 in patients with select advanced malignant tumors, marking a significant step in cancer treatment research.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 study titled A Multicenter, Randomized, Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Pharmacokinetics, Efficacy and Safety of Deucravacitinib (BMS-986165) in Pediatric Subjects With Moderate to Severe Plaque Psoriasis. The study aims to assess the drug levels, efficacy, and safety of Deucravacitinib in children aged 4 to less than 18 years with moderate to severe plaque psoriasis, highlighting its potential significance in pediatric dermatology.
Study Overview: Bristol-Myers Squibb is conducting a Phase 1 study titled ‘A Phase 1, Open-label Study of BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer.’ The study aims to evaluate the safety, tolerability, and preliminary efficacy of BMS-986460 in men with this advanced form of prostate cancer, which is significant for developing new treatment options.
Study Overview: Bristol-Myers Squibb is conducting a Phase 3b study titled ‘A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants.’ The study aims to evaluate the efficacy and safety of Luspatercept at its maximum approved dose in participants with low-risk Myelodysplastic Syndrome (LR-MDS) who require red blood cell transfusions. This study is significant as it addresses the treatment needs of patients with specific risk profiles, potentially improving their quality of life.
Study Overview: Bristol-Myers Squibb Company recently completed a post-marketing surveillance study titled ‘Empliciti® (Elotuzumab) Post-Marketing Surveillance Study for Patients With Multiple Myeloma in Taiwan.’ The study aimed to evaluate the safety of elotuzumab when used with pomalidomide and dexamethasone, and separately with lenalidomide and dexamethasone, in treating relapsed and refractory multiple myeloma (RRMM) in patients who had undergone prior therapies. This research is significant as it provides crucial safety data for these drug combinations in a real-world setting.
On July 31, 2025, Bristol Myers Squibb reported its financial results for the second quarter of 2025, highlighting a total revenue of $12.3 billion, a 1% increase from the previous year. The company’s Growth Portfolio revenues rose by 18%, driven by strong performances in its immuno-oncology products, while the Legacy Portfolio saw a decline due to generic competition and Medicare Part D impacts. The company raised its 2025 revenue guidance and emphasized its focus on advancing transformational medicines and pipeline opportunities to sustain long-term growth.
The most recent analyst rating on (BMY) stock is a Buy with a $64.00 price target. To see the full list of analyst forecasts on Bristol-Myers Squibb stock, see the BMY Stock Forecast page.